Compare AVO & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVO | ODTX |
|---|---|---|
| Founded | 1983 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2020 | 2025 |
| Metric | AVO | ODTX |
|---|---|---|
| Price | $13.13 | $25.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | ★ 656.0K | 126.1K |
| Earning Date | 06-04-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.92 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,391,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.68 | N/A |
| 52 Week Low | $10.07 | $15.10 |
| 52 Week High | $15.53 | $26.49 |
| Indicator | AVO | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.40 | 71.31 |
| Support Level | $13.03 | $19.84 |
| Resistance Level | $14.11 | N/A |
| Average True Range (ATR) | 0.42 | 1.88 |
| MACD | 0.02 | 0.53 |
| Stochastic Oscillator | 73.79 | 75.94 |
Mission Produce Inc produces, packs, and distributes mainly Hass avocados to retail, wholesale, and food service customers, offering pre-ripe and ripened fruit tailored to customer specifications through its network of ripening facilities. The Company operates through three segments: Marketing & Distribution, which sources and distributes fruit globally and generates the majority of revenue; International Farming, which owns and operates avocado orchards and supplies fruit mainly to Marketing & Distribution, with operations principally in Peru and Guatemala; and Blueberries, which farms blueberries sold under an exclusive marketing agreement. The Company's operations span Peru, the United States, Guatemala, Mexico, Europe, and Canada.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.